Fulcrum Capital LLC Invests $2.33 Million in DexCom, Inc. (NASDAQ:DXCM)

Fulcrum Capital LLC purchased a new position in DexCom, Inc. (NASDAQ:DXCM - Free Report) in the 1st quarter, according to the company in its most recent disclosure with the SEC. The fund purchased 34,072 shares of the medical device company's stock, valued at approximately $2,327,000.

A number of other hedge funds also recently bought and sold shares of DXCM. Private Trust Co. NA lifted its stake in shares of DexCom by 266.3% in the fourth quarter. Private Trust Co. NA now owns 337 shares of the medical device company's stock worth $26,000 after buying an additional 245 shares in the last quarter. Optiver Holding B.V. bought a new position in DexCom in the 4th quarter valued at approximately $33,000. TD Private Client Wealth LLC boosted its stake in DexCom by 62.8% during the 4th quarter. TD Private Client Wealth LLC now owns 433 shares of the medical device company's stock valued at $34,000 after purchasing an additional 167 shares during the last quarter. Larson Financial Group LLC increased its holdings in shares of DexCom by 40.5% in the 4th quarter. Larson Financial Group LLC now owns 475 shares of the medical device company's stock worth $37,000 after purchasing an additional 137 shares in the last quarter. Finally, Heck Capital Advisors LLC purchased a new position in shares of DexCom in the fourth quarter worth $38,000. Institutional investors own 97.75% of the company's stock.

DexCom Trading Down 0.9%

Shares of DXCM stock traded down $0.80 on Wednesday, reaching $85.99. 635,258 shares of the company's stock were exchanged, compared to its average volume of 4,334,846. The company's fifty day simple moving average is $75.28 and its 200 day simple moving average is $78.84. DexCom, Inc. has a 52 week low of $57.52 and a 52 week high of $120.48. The company has a current ratio of 1.47, a quick ratio of 1.28 and a debt-to-equity ratio of 0.59. The stock has a market capitalization of $33.72 billion, a PE ratio of 60.13, a P/E/G ratio of 2.30 and a beta of 1.43.

DexCom (NASDAQ:DXCM - Get Free Report) last issued its earnings results on Thursday, May 1st. The medical device company reported $0.32 earnings per share (EPS) for the quarter, missing analysts' consensus estimates of $0.33 by ($0.01). The company had revenue of $1.04 billion for the quarter, compared to analysts' expectations of $1.02 billion. DexCom had a net margin of 14.29% and a return on equity of 30.14%. The firm's revenue for the quarter was up 12.5% compared to the same quarter last year. During the same period in the prior year, the firm posted $0.32 earnings per share. As a group, analysts forecast that DexCom, Inc. will post 2.03 EPS for the current year.

Analysts Set New Price Targets

Several research firms recently commented on DXCM. The Goldman Sachs Group assumed coverage on DexCom in a research report on Friday, May 30th. They set a "buy" rating and a $104.00 price objective on the stock. Wells Fargo & Company restated an "overweight" rating on shares of DexCom in a report on Saturday, March 8th. Morgan Stanley lifted their target price on shares of DexCom from $75.00 to $82.00 and gave the stock an "equal weight" rating in a research report on Friday, February 14th. Piper Sandler lowered their price target on DexCom from $100.00 to $90.00 and set an "overweight" rating on the stock in a report on Friday, May 2nd. Finally, Canaccord Genuity Group raised their price target on DexCom from $103.00 to $106.00 and gave the stock a "buy" rating in a research note on Friday, May 2nd. Five research analysts have rated the stock with a hold rating, fourteen have issued a buy rating and three have given a strong buy rating to the stock. Based on data from MarketBeat.com, the company currently has a consensus rating of "Moderate Buy" and an average price target of $98.32.

Insider Activity at DexCom

In related news, CEO Kevin R. Sayer sold 32,498 shares of DexCom stock in a transaction that occurred on Wednesday, March 12th. The shares were sold at an average price of $70.38, for a total transaction of $2,287,209.24. Following the transaction, the chief executive officer now directly owns 372,029 shares of the company's stock, valued at $26,183,401.02. This trade represents a 8.03% decrease in their ownership of the stock. The sale was disclosed in a filing with the SEC, which is available through this link. Also, EVP Sadie Stern sold 6,184 shares of DexCom stock in a transaction dated Tuesday, May 27th. The shares were sold at an average price of $85.11, for a total value of $526,320.24. Following the completion of the transaction, the executive vice president now owns 109,621 shares in the company, valued at $9,329,843.31. This trade represents a 5.34% decrease in their position. The disclosure for this sale can be found here. Insiders sold 83,110 shares of company stock worth $6,103,505 over the last three months. 0.32% of the stock is owned by corporate insiders.

DexCom Profile

DexCom, Inc, a medical device company, focuses on the design, development, and commercialization of continuous glucose monitoring (CGM) systems in the United States and internationally. The company provides its systems for use by people with diabetes, as well as for use by healthcare providers. Its products include Dexcom G6 and Dexcom G7, integrated CGM systems for diabetes management; Dexcom Share, a remote monitoring system; Dexcom Real-Time API, which enables authorized third-party software developers to integrate real-time CGM data into their digital health apps and devices; and Dexcom ONE, that is designed to replace finger stick blood glucose testing for diabetes treatment decisions.